Efficacy of ronopterin (vas203) in patients with moderate and severe traumatic brain injury (nostra phase iii trial): study protocol of a confirmatory, placebo-controlled, randomised, double blind, multi-centre study

HIGHLIGHTS

• who: Frank Tegtmeier from the vasopharm GmbH, Würzburg, Germany have published the article: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebo-controlled, randomised, double blind, multi-centre study, in the Journal: (JOURNAL) of 05/Nov/2018
• what: The trial aims to provide evidence on the efficacy and safety of Ronopterin in patients with traumatic brain injury. In an exploratory analysis the study showed promising results by significantly improving clinical outcome despite the small number of patients enrolled . The aim . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.